This is the authors' abstract. We don't add key points for this paper.
To update the assessment of PML risk with natalizumab EID in comparison with Q4W dosing using TOUCH data as of June 30, 2023.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ryerson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: